This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Koster, A. Articles by Fischer, T. Search for Related Content PubMed Articles by Koster, A. Articles by Fischer, T. Social Bookmarking                   What's this?

Management of Patients with Heparin-Induced Thrombocytopenia During Cardiac Surgery

Department of Anesthesia, Deutsches Herzzentrum Berlin, Germany; Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; Koster{at}dhzb.de

Thomas Fischer, MD

Department of Anesthesia, Park-Schönfeld-Klinik, Kassel, Germany

The role of heparin-induced thrombocytopenia and its possibly severe complications in patients undergoing cardiac surgery is increasingly appreciated. Increasing evidence indicates that in patients without the presence of antibodies, unfractionated heparins can be safely used during cardiopulmonary bypass, if their employment is restricted to this short period. This strategy is the first choice in patients with a current negative status of antibodies and in patients in whom surgery can be delayed until antibodies cannot be detected by laboratory tests. To date, however, no alternative anticoagulant to heparin during cardiopulmonary bypass has been approved. With the introduction of the class of direct thrombin inhibitors, effective anticoagulants have become available; however, they have no antidote and require specific monitoring. The availability of direct thrombin inhibitors is currently restricted. The administration of unfractionated heparin with anti-platelet agents such as prostaglandins or the short-acting platelet glycoprotein llb/Illa antagonist tirofiban is another option. Despite successful use of these strategies in fairly large numbers of patients, recent information suggests that in the case of tirofiban, renal failure may cause persistence of the agent with subsequent severe hemorrhage. If surgery is restricted to coronary artery bypass grafting, recent data show that off-pump strategies with use of the direct thrombin inhibitor bivalirudin appear to be a promising option. Therefore, if surgery cannot be postponed, the anticoagulation protocol and the surgical strategy must be adjusted to the condition of the patient and the experience of the center in order to reduce the risk of these "offlabel" strategies.

Seminars in Cardiothoracic and Vascular Anesthesia, Vol. 7, No. 4, 411-416 (2003)
DOI: 10.1177/108925320300700405


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				K. A. Tanaka, F. Szlam, H. Y. Sun, T. Taketomi, and J. H. Levy Thrombin Generation Assay and Viscoelastic Coagulation Monitors Demonstrate Differences in the Mode of Thrombin Inhibition Between Unfractionated Heparin and Bivalirudin Anesth. Analg., October 1, 2007; 105(4): 933 - 939. [Abstract] [Full Text] [PDF]